MannKind Corp
NASDAQ:MNKD

Watchlist Manager
MannKind Corp Logo
MannKind Corp
NASDAQ:MNKD
Watchlist
Price: 4.1 USD 4.33% Market Closed
Market Cap: 1.2B USD

Net Margin
MannKind Corp

10%
Current
-43%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10%
=
Net Income
29.6m
/
Revenue
297.6m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
MannKind Corp
NASDAQ:MNKD
1.2B USD
10%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
337.9B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
165.8B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
141.4B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.6B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
130.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.9B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

MannKind Corp
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

MannKind Corp. stands as a fascinating player in the biotech landscape, primarily due to its focus on innovative drug delivery systems that aim to redefine patient experience and therapeutic efficacy. Founded with the intention of creating transformative medicinal solutions, the company is best known for its flagship product, Afrezza, an inhalable form of insulin designed to manage diabetes. This unique delivery method not only enhances the speed at which insulin begins to act within the body, but also offers a discreet and user-friendly alternative to traditional injectable options. Driven by a blend of science and practicality, MannKind's efforts are centered around enhancing quality of life for patients, marking its territory in a niche, yet crucial, segment of the pharmaceutical market. MannKind generates revenue by producing and distributing its highly specialized products, leveraging partnerships with larger pharmaceutical companies to expand its market reach. By optimizing their drug delivery systems, they aim to position themselves competitively, offering solutions that stand out in a crowded industry. Beyond Afrezza, MannKind seeks to harness its proprietary Technosphere technology platform, exploring applications beyond diabetes to potentially treat other conditions. This approach not only broadens their market horizon but also diversifies potential revenue streams, allowing MannKind to maintain a steady course in the volatile currents of the biotech sector. In essence, MannKind's business strategy is a calculated blend of ingenuity and collaboration, with a clear emphasis on meeting unmet medical needs effectively.

MNKD Intrinsic Value
4.66 USD
Undervaluation 12%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10%
=
Net Income
29.6m
/
Revenue
297.6m
What is the Net Margin of MannKind Corp?

Based on MannKind Corp's most recent financial statements, the company has Net Margin of 10%.

Back to Top